Bristol-Myers Squibb has expanded its partnership with Foundation Medicine to develop a companion diagnostic for an investigational targeted cancer th...
Bullish
Bristol-Myers Squibb (BMY) is set to report its Q1 earnings tomorrow before market open. Analysts are predicting a 4.5% year-over-year revenue decline...
Neutral
This article identifies Bristol Myers Squibb, Medtronic, and Gilead Sciences as top dividend-paying healthcare stocks. Despite facing challenges like ...
Neutral
Comerica Bank reduced its stake in Bristol Myers Squibb Company by 3.8% in the fourth quarter, selling 25,379 shares and owning a total of 637,744 sha...
Neutral
D.A. Davidson & CO. increased its stake in Bristol Myers Squibb Company by 10.7% in the fourth quarter, acquiring an additional 28,410 shares, bringin...
Bearish
Ashton Thomas Private Wealth LLC reduced its stake in Bristol Myers Squibb (BMY) by 18.2% in the fourth quarter of 2. It now holds 130,991 shares valu...
Neutral
Concurrent Investment Advisors LLC significantly increased its stake in Bristol Myers Squibb (BMY) by 204% during the fourth quarter, adding 114,857 s...
Neutral
Advisors Capital Management LLC increased its stake in Bristol Myers Squibb (BMY) by 2.3% in Q4, acquiring an additional 21,015 shares to reach a tota...
Neutral
Despite share price declines, some investors continue to hold healthcare stocks like Medtronic, Sanofi, and Bristol Myers Squibb due to their attracti...
Bullish
Bristol Myers Squibb and Pfizer have added their anticoagulant drug Eliquis to the Cost Plus Drugs portal, expanding direct-to-patient options for cas...
Neutral
Some healthcare stocks have seen declines recently, but three companies — Medtronic, Sanofi, and Bristol Myers Squibb — offer significant dividend yie...
Bristol-Myers Squibb (BMY) stock is trading at US$58.71, with a widely followed narrative suggesting it is 9.7% undervalued at a fair value of $65. De...
Bristol-Myers Squibb (BMY) has seen a 27% rally over the last year, prompting questions about its current valuation. A Discounted Cash Flow (DCF) anal...
Neutral
Evergreen Capital Management LLC cut its stake in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 32.4% in the fourth quarter, acco...
Bristol Myers Squibb (NYSE:BMY) has announced an expanded collaboration with Foundation Medicine for a next-generation sequencing companion diagnostic...
Bullish
Bristol-Myers Squibb (US0897961004) is highlighted for its strong position in oncology and immunology, driven by blockbuster drugs and a research-focu...
Neutral
Bristol-Myers Squibb (BMS) stock (US0897961004) is positioned as a key player in the biotech sector due to its strong focus on oncology and immunology...
Neutral
Wall Street Zen upgraded Bristol Myers Squibb (BMY) from "buy" to "strong-buy," causing the stock to trade up 2.1% to $60.21. Despite missing quarterl...
Bullish
Bristol-Myers Squibb leverages its strong oncology portfolio, focused R&D, and strategic acquisitions to drive growth and maintain a competitive edge,...
Bullish
Bristol-Myers Squibb's strong position in oncology treatments, with blockbuster drugs like Opdivo and Eliquis, offers resilience in the volatile biote...